JP Morgan Investment Insulates Limeglass Start-Up Amid Coronavirus

The research start-up is growing its team and is in discussions with clients, despite Covid-19 disruption, after the bank acquired a stake.

plant with money

Research start-up Limeglass is riding out the coronavirus storm, thanks to investment from JP Morgan.

Limeglass announced late last year that the bank had acquired an undisclosed stake, and the start-up has since used the funding to hire more people and improve its product, which filters financial research documents to find the most relevant information.

“The investment was a game-changer for us. Clearly, it is helping us through [the coronavirus pandemic], but even before that, we were able

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Waterstechnology? View our subscription options

Register for free

Access two articles, our IMD and Waters Wraps, plus a member newsletter. Find out more.

All fields are mandatory unless otherwise highlighted.

This address will be used to create your account

A tech revolution in an old-school industry: FX

FX is in a state of transition, as asset managers and financial firms explore modernizing their operating processes. But manual processes persist. MillTechFX’s Eric Huttman makes the case for doubling down on new technology and embracing automation to increase operational efficiency in FX.

Most read articles loading...

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here